share_log

SciSparc | 6-K: Report of foreign private issuer (related to financial reporting)

SciSparc | 6-K: Report of foreign private issuer (related to financial reporting)

SciSparc | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/08/19 19:02

Moomoo AI 已提取核心信息

SciSparc Ltd. has entered into an exclusive patent license agreement with Polyrizon Ltd. on August 13, 2024, for the out-licensing of its SCI-160 pain therapy program. Under the agreement, Polyrizon will receive exclusive, royalty-bearing global rights to develop and sublicense the assets, while SciSparc will receive Polyrizon securities valued at $3 million and potential milestone fees of approximately $3 million if certain development targets are met.The licensed SCI-160 program is an innovative synthetic combination of cannabinoids and N-acylethanolamines for pain treatment. Pre-clinical studies have shown the treatment to be well-tolerated with comparable or superior analgesic effects to high-dose morphine, without significant adverse effects in both acute and chronic pain conditions.The agreement also includes the termination of a previous co-development agreement dated May 30, 2022, between the two companies. Notably, SciSparc's CEO and CFO Oz Adler serves as a board member of Polyrizon, and the deal structure allows SciSparc to potentially benefit from royalties without additional development investment.
SciSparc Ltd. has entered into an exclusive patent license agreement with Polyrizon Ltd. on August 13, 2024, for the out-licensing of its SCI-160 pain therapy program. Under the agreement, Polyrizon will receive exclusive, royalty-bearing global rights to develop and sublicense the assets, while SciSparc will receive Polyrizon securities valued at $3 million and potential milestone fees of approximately $3 million if certain development targets are met.The licensed SCI-160 program is an innovative synthetic combination of cannabinoids and N-acylethanolamines for pain treatment. Pre-clinical studies have shown the treatment to be well-tolerated with comparable or superior analgesic effects to high-dose morphine, without significant adverse effects in both acute and chronic pain conditions.The agreement also includes the termination of a previous co-development agreement dated May 30, 2022, between the two companies. Notably, SciSparc's CEO and CFO Oz Adler serves as a board member of Polyrizon, and the deal structure allows SciSparc to potentially benefit from royalties without additional development investment.
SciSparc有限公司于2024年8月13日与Polyrizon有限公司签订了一项独占专利许可协议，许可其SCI-160疼痛治疗项目。根据协议，Polyrizon将获得独占的、需支付版税的全球权利，以开发和再许可这些资产，而SciSparc将获得价值300万的Polyrizon证券，以及在达到特定开发目标时潜在的约300万的里程碑费用。被许可的SCI-160项目是一种创新的合成大麻素和N-乙酰乙醇胺的结合，用于疼痛治疗。临床前研究表明，该治疗方案耐受性良好，与高剂量吗啡相比具有相当或更优的镇痛效果，并且在急性和慢性疼痛条件下没有显著的不良反应。该协议还包括终止两家公司之间于2022年5月30日签署的之前的共同开发协议。值得注意的是，SciSparc的首席执行官兼首席财务官Oz Adler在Polyrizon担任董事会成员，而协议结构使SciSparc有可能从版税中获益，而无需额外的开发投资。
SciSparc有限公司于2024年8月13日与Polyrizon有限公司签订了一项独占专利许可协议，许可其SCI-160疼痛治疗项目。根据协议，Polyrizon将获得独占的、需支付版税的全球权利，以开发和再许可这些资产，而SciSparc将获得价值300万的Polyrizon证券，以及在达到特定开发目标时潜在的约300万的里程碑费用。被许可的SCI-160项目是一种创新的合成大麻素和N-乙酰乙醇胺的结合，用于疼痛治疗。临床前研究表明，该治疗方案耐受性良好，与高剂量吗啡相比具有相当或更优的镇痛效果，并且在急性和慢性疼痛条件下没有显著的不良反应。该协议还包括终止两家公司之间于2022年5月30日签署的之前的共同开发协议。值得注意的是，SciSparc的首席执行官兼首席财务官Oz Adler在Polyrizon担任董事会成员，而协议结构使SciSparc有可能从版税中获益，而无需额外的开发投资。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    美联储暂停降息，你如何调整持仓？
    美联储宣布基准利率维持在4.25%—4.50%不变，符合市场预期。你会如何配置资产？ 展开
    联邦公开市场委员会新闻发布会，2025年1月29日